

Cambridge International AS & A Level

BIOLOGY

9700/42

Paper 4 A Level Structured Questions

October/November 2024

MARK SCHEME

Maximum Mark: 100

Published

This mark scheme is published as an aid to teachers and candidates, to indicate the requirements of the examination. It shows the basis on which Examiners were instructed to award marks. It does not indicate the details of the discussions that took place at an Examiners' meeting before marking began, which would have considered the acceptability of alternative answers.

Mark schemes should be read in conjunction with the question paper and the Principal Examiner Report for Teachers.

Cambridge International will not enter into discussions about these mark schemes.

Cambridge International is publishing the mark schemes for the October/November 2024 series for most Cambridge IGCSE, Cambridge International A and AS Level components, and some Cambridge O Level components.

This document consists of **19** printed pages.

PUBLISHED**Generic Marking Principles**

These general marking principles must be applied by all examiners when marking candidate answers. They should be applied alongside the specific content of the mark scheme or generic level descriptions for a question. Each question paper and mark scheme will also comply with these marking principles.

GENERIC MARKING PRINCIPLE 1:

Marks must be awarded in line with:

- the specific content of the mark scheme or the generic level descriptors for the question
- the specific skills defined in the mark scheme or in the generic level descriptors for the question
- the standard of response required by a candidate as exemplified by the standardisation scripts.

GENERIC MARKING PRINCIPLE 2:

Marks awarded are always **whole marks** (not half marks, or other fractions).

GENERIC MARKING PRINCIPLE 3:

Marks must be awarded **positively**:

- marks are awarded for correct/valid answers, as defined in the mark scheme. However, credit is given for valid answers which go beyond the scope of the syllabus and mark scheme, referring to your Team Leader as appropriate
- marks are awarded when candidates clearly demonstrate what they know and can do
- marks are not deducted for errors
- marks are not deducted for omissions
- answers should only be judged on the quality of spelling, punctuation and grammar when these features are specifically assessed by the question as indicated by the mark scheme. The meaning, however, should be unambiguous.

GENERIC MARKING PRINCIPLE 4:

Rules must be applied consistently, e.g. in situations where candidates have not followed instructions or in the application of generic level descriptors.

PUBLISHED**GENERIC MARKING PRINCIPLE 5:**

Marks should be awarded using the full range of marks defined in the mark scheme for the question (however; the use of the full mark range may be limited according to the quality of the candidate responses seen).

GENERIC MARKING PRINCIPLE 6:

Marks awarded are based solely on the requirements as defined in the mark scheme. Marks should not be awarded with grade thresholds or grade descriptors in mind.

Science-Specific Marking Principles

1 Examiners should consider the context and scientific use of any keywords when awarding marks. Although keywords may be present, marks should not be awarded if the keywords are used incorrectly.

2 The examiner should not choose between contradictory statements given in the same question part, and credit should not be awarded for any correct statement that is contradicted within the same question part. Wrong science that is irrelevant to the question should be ignored.

3 Although spellings do not have to be correct, spellings of syllabus terms must allow for clear and unambiguous separation from other syllabus terms with which they may be confused (e.g. ethane / ethene, glucagon / glycogen, refraction / reflection).

4 The error carried forward (ecf) principle should be applied, where appropriate. If an incorrect answer is subsequently used in a scientifically correct way, the candidate should be awarded these subsequent marking points. Further guidance will be included in the mark scheme where necessary and any exceptions to this general principle will be noted.

5 'List rule' guidance

For questions that require *n* responses (e.g. State **two** reasons ...):

- The response should be read as continuous prose, even when numbered answer spaces are provided.
- Any response marked *ignore* in the mark scheme should not count towards *n*.
- Incorrect responses should not be awarded credit but will still count towards *n*.
- Read the entire response to check for any responses that contradict those that would otherwise be credited. Credit should **not** be awarded for any responses that are contradicted within the rest of the response. Where two responses contradict one another, this should be treated as a single incorrect response.
- Non-contradictory responses after the first *n* responses may be ignored even if they include incorrect science.

PUBLISHED**6** Calculation specific guidance

Correct answers to calculations should be given full credit even if there is no working or incorrect working, **unless** the question states 'show your working'.

For questions in which the number of significant figures required is not stated, credit should be awarded for correct answers when rounded by the examiner to the number of significant figures given in the mark scheme. This may not apply to measured values.

For answers given in standard form (e.g. $a \times 10^n$) in which the convention of restricting the value of the coefficient (a) to a value between 1 and 10 is not followed, credit may still be awarded if the answer can be converted to the answer given in the mark scheme.

Unless a separate mark is given for a unit, a missing or incorrect unit will normally mean that the final calculation mark is not awarded. Exceptions to this general principle will be noted in the mark scheme.

7 Guidance for chemical equations

Multiples / fractions of coefficients used in chemical equations are acceptable unless stated otherwise in the mark scheme.

State symbols given in an equation should be ignored unless asked for in the question or stated otherwise in the mark scheme.

Mark scheme abbreviations

| | |
|------------------|---|
| ; | separates marking points |
| / | alternative answers for the same point |
| A | accept (for answers correctly cued by the question, or by extra guidance) |
| R | reject |
| I | ignore |
| () | the word / phrase in brackets is not required, but sets the context |
| AW | alternative wording (where responses vary more than usual) |
| underline | actual word given must be used by candidate (grammatical variants accepted) |
| max | indicates the maximum number of marks that can be given |
| ora | or reverse argument |
| mp | marking point (with relevant number) |
| ecf | error carried forward |
| AVP | alternative valid point |

PUBLISHED

| Question | Answer | Marks | | | | | | | | | | | | | | | | |
|---|--|---|---|--------------------|--|---------|------|-------------|---|----------------|-------------|-------------|---|------|------|-----------|---|----------|
| 1(a)(i) | A – podocyte ; B – (capillary) endothelial cell ; | 2 | | | | | | | | | | | | | | | | |
| 1(a)(ii) | high(er) , hydrostatic / blood, pressure ; ignore <i>ref. to</i> water potential <u>basement membrane</u> acts as a filter / only small molecules can pass through <u>basement membrane</u> ; | 2 | | | | | | | | | | | | | | | | |
| 1(b) | <table border="1" data-bbox="338 451 1153 778"> <thead> <tr> <th data-bbox="338 451 593 584">component of blood plasma in glomerulus</th> <th data-bbox="593 451 871 584">component in newly formed glomerular filtrate</th> <th data-bbox="871 451 1120 584">component in urine</th> <th data-bbox="1120 451 1153 584"></th> </tr> </thead> <tbody> <tr> <td data-bbox="338 584 593 649">glucose</td> <td data-bbox="593 584 871 649">same</td> <td data-bbox="871 584 1120 649">not present</td> <td data-bbox="1120 584 1153 649">;</td> </tr> <tr> <td data-bbox="338 649 593 715">large proteins</td> <td data-bbox="593 649 871 715">not present</td> <td data-bbox="871 649 1120 715">not present</td> <td data-bbox="1120 649 1153 715">;</td> </tr> <tr> <td data-bbox="338 715 593 778">urea</td> <td data-bbox="593 715 871 778">same</td> <td data-bbox="871 715 1120 778">increased</td> <td data-bbox="1120 715 1153 778">;</td> </tr> </tbody> </table> | component of blood plasma in glomerulus | component in newly formed glomerular filtrate | component in urine | | glucose | same | not present | ; | large proteins | not present | not present | ; | urea | same | increased | ; | 3 |
| component of blood plasma in glomerulus | component in newly formed glomerular filtrate | component in urine | | | | | | | | | | | | | | | | |
| glucose | same | not present | ; | | | | | | | | | | | | | | | |
| large proteins | not present | not present | ; | | | | | | | | | | | | | | | |
| urea | same | increased | ; | | | | | | | | | | | | | | | |
| 1(c) | <i>posterior pituitary gland</i> – releases (more) ADH ; A secretes <i>kidney</i> – reabsorbs more water / urine more concentrated / lower volume of urine ; OR (more) aquaporins added to membrane of collecting duct (cells) / membrane of collecting duct (cells) more permeable to water ; | 2 | | | | | | | | | | | | | | | | |

PUBLISHED

| Question | Answer | Marks |
|-----------------|--|--------------|
| 2(a) | <p><i>any six from:</i></p> <ol style="list-style-type: none"> 1 mutation / described ; 2 genetic drift / described ; 3 founder effect / group separated from main population to found a new population ; 4 bottleneck effect / large fall in population ; 5 natural / directional / disruptive, selection ; ignore artificial / stabilising selection 6 migration / gene flow / interbreeding between populations ; 7 genetic recombination / linkage groups broken / crossing over ; 8 AVP ; e.g. effect larger in small populations | 6 |
| 2(b) | <p><i>any three from:</i></p> <ol style="list-style-type: none"> 1 inbreeding / described ; 2 produces homozygous plants / increases homozygosity ; 3 outbreeding / described ; 4 hybridisation / producing a hybrid ; 5 hybrids / offspring / F1, are (all) heterozygotes / have increased heterozygosity ; | 3 |

| Question | Answer | Marks |
|----------|--|----------|
| 3(a) | <p>any three from:</p> <ol style="list-style-type: none"> 1 manipulation of, genetic material / gene / DNA or described ; 2 <i>ref. to</i> gene / allele, transfer (into, cell / organism) or described ; 3 expression of gene ; 4 (named) phenotype modified / (named) protein produced ; 5 AVP ; e.g. <i>ref. to</i> gene editing / produce GMO | 3 |
| 3(b)(i) | <p>any three from:</p> <ol style="list-style-type: none"> 1 add, healthy / normal / correct / functional, gene / allele, to virus ; 2 inject virus into eye ; 3 gene integrated into (eye cell) genome / DNA ; 4 gene / allele, expressed to produce functioning, protein / enzyme ; 5 AVP ; e.g. adeno-associated virus / AAV voretigene neparvovec (drug) | 3 |
| 3(b)(ii) | <p>any one from:</p> <ol style="list-style-type: none"> 1 easily accessible / easy to inject ; 2 low risk of immune response ; 3 (eye small in size so) small amount of gene therapy treatment needed / AW ; | 1 |

| Question | Answer | Marks | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---------------|--|---------------|------------------------------|--|--|-----------------|-------------|---|------|------|---|-------|-------|---|-------|-------|---|------|-------|---|-------|-------|---|----------------|-------|---|-------|-------|---|-------|-------|---|-------|-------|----|-------|-------|----|-------|-------|---|
| 3(c)(i) | <p>any three from:</p> <p>1 (overall) improvement in acuity of both eyes or (overall visual) acuity of both eyes becomes more negative ;</p> <p>2 treated eye, has more improved acuity / has more negative (visual) acuity ; ora</p> <p>3 <i>ref. to</i> anomalous result at month 9 / result that does not fit the pattern at month 9 ;</p> <p>4 data quote – values of one eye at two months or values of both eyes at one month ;</p> <table border="1" data-bbox="338 555 943 1374"> <thead> <tr> <th data-bbox="338 555 465 644">time / months</th> <th colspan="2" data-bbox="465 555 943 608">change in visual acuity / au</th> </tr> <tr> <td data-bbox="338 644 465 735"></td> <th data-bbox="465 644 680 735">eye not treated</th> <th data-bbox="680 644 943 735">eye treated</th> </tr> </thead> <tbody> <tr> <td data-bbox="338 735 465 794">0</td> <td data-bbox="465 735 680 794">0.00</td> <td data-bbox="680 735 943 794">0.00</td> </tr> <tr> <td data-bbox="338 794 465 853">1</td> <td data-bbox="465 794 680 853">-0.12</td> <td data-bbox="680 794 943 853">-0.20</td> </tr> <tr> <td data-bbox="338 853 465 912">2</td> <td data-bbox="465 853 680 912">+0.02</td> <td data-bbox="680 853 943 912">-0.40</td> </tr> <tr> <td data-bbox="338 912 465 971">3</td> <td data-bbox="465 912 680 971">0.00</td> <td data-bbox="680 912 943 971">-0.50</td> </tr> <tr> <td data-bbox="338 971 465 1031">4</td> <td data-bbox="465 971 680 1031">-0.13</td> <td data-bbox="680 971 943 1031">-0.52</td> </tr> <tr> <td data-bbox="338 1031 465 1090">5</td> <td data-bbox="465 1031 680 1090">-0.22 or -0.23</td> <td data-bbox="680 1031 943 1090">-0.52</td> </tr> <tr> <td data-bbox="338 1090 465 1149">6</td> <td data-bbox="465 1090 680 1149">-0.15</td> <td data-bbox="680 1090 943 1149">-0.54</td> </tr> <tr> <td data-bbox="338 1149 465 1208">7</td> <td data-bbox="465 1149 680 1208">-0.12</td> <td data-bbox="680 1149 943 1208">-0.50</td> </tr> <tr> <td data-bbox="338 1208 465 1267">9</td> <td data-bbox="465 1208 680 1267">-0.15</td> <td data-bbox="680 1208 943 1267">-0.33</td> </tr> <tr> <td data-bbox="338 1267 465 1326">10</td> <td data-bbox="465 1267 680 1326">-0.08</td> <td data-bbox="680 1267 943 1326">-0.52</td> </tr> <tr> <td data-bbox="338 1326 465 1374">12</td> <td data-bbox="465 1326 680 1374">-0.12</td> <td data-bbox="680 1326 943 1374">-0.54</td> </tr> </tbody> </table> | time / months | change in visual acuity / au | | | eye not treated | eye treated | 0 | 0.00 | 0.00 | 1 | -0.12 | -0.20 | 2 | +0.02 | -0.40 | 3 | 0.00 | -0.50 | 4 | -0.13 | -0.52 | 5 | -0.22 or -0.23 | -0.52 | 6 | -0.15 | -0.54 | 7 | -0.12 | -0.50 | 9 | -0.15 | -0.33 | 10 | -0.08 | -0.52 | 12 | -0.12 | -0.54 | 3 |
| time / months | change in visual acuity / au | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | eye not treated | eye treated | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 0 | 0.00 | 0.00 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | -0.12 | -0.20 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | +0.02 | -0.40 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | 0.00 | -0.50 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | -0.13 | -0.52 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | -0.22 or -0.23 | -0.52 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6 | -0.15 | -0.54 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 7 | -0.12 | -0.50 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | -0.15 | -0.33 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 | -0.08 | -0.52 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 12 | -0.12 | -0.54 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| Question | Answer | Marks |
|----------|--|----------|
| 3(c)(ii) | <p>any three from:</p> <ol style="list-style-type: none"> 1 mutated DNA is, deleted / removed / cut out or DNA replaced with normal DNA ; Ignore exon X is deleted as this is mRNA not DNA Reject gene deleted / cut out 2 specific (locations) / between exon 26 and exon 27, (in the genome) ; 3 functional protein / CEP290, now made OR correct functioning of photoreceptors ; 4 acts on person's own DNA ; 5 AVP ; e.g. STOP codon no longer present | 3 |

| Question | Answer | Marks |
|----------|--|----------|
| 4(a) | <p><i>parental genotype</i> Rr x Rr</p> <p>AND</p> <p><i>gametes</i> (R) (r) (R) (r) ;</p> <p><i>offspring genotype</i> RR Rr (Rr) rr ;</p> <p style="padding-left: 100px;">red red red yellow ;</p> | 3 |

| Question | Answer | Marks |
|----------|--|----------|
| 4(b) | 1 <i>ratio=9:3:3:1 ;</i> <i>any two from:</i> 2 independent / random, assortment ; 3 of, homologous chromosomes / bivalents / sister chromatids ; 4 stage of meiosis ; e.g. metaphase 1 or metaphase 11 Ignore <i>ref. to crossing over / recombinants</i> | 3 |

| Question | Answer | | | Marks | | | | | | | | | | | | | | | | |
|--|--|----------------------|-------------------------|----------------------|------------------------------|---|--|--|--|---|--|--|---|--|---|--|--|--|-----|----------|
| 5(a) | <table border="1"> <thead> <tr> <th data-bbox="331 730 828 831">statement</th> <th data-bbox="837 730 1077 831">discontinuous variation</th> <th data-bbox="1077 730 1267 831">continuous variation</th> </tr> </thead> <tbody> <tr> <td data-bbox="331 831 828 896">often involves one gene only</td> <td data-bbox="837 831 1077 896">✓</td> <td data-bbox="1077 831 1267 896"></td> </tr> <tr> <td data-bbox="331 896 828 997">environmental factors may affect gene expression</td> <td data-bbox="837 896 1077 997"></td> <td data-bbox="1077 896 1267 997">✓</td> </tr> <tr> <td data-bbox="331 997 828 1098">there is an additive effect of genes that contributes to the phenotype</td> <td data-bbox="837 997 1077 1098"></td> <td data-bbox="1077 997 1267 1098">✓</td> </tr> <tr> <td data-bbox="331 1098 828 1230">there are distinct differences between the various forms of a characteristic</td> <td data-bbox="837 1098 1077 1230">✓</td> <td data-bbox="1077 1098 1267 1230"></td> </tr> </tbody> </table> | statement | discontinuous variation | continuous variation | often involves one gene only | ✓ | | environmental factors may affect gene expression | | ✓ | there is an additive effect of genes that contributes to the phenotype | | ✓ | there are distinct differences between the various forms of a characteristic | ✓ | | | | ;;; | 4 |
| statement | discontinuous variation | continuous variation | | | | | | | | | | | | | | | | | | |
| often involves one gene only | ✓ | | | | | | | | | | | | | | | | | | | |
| environmental factors may affect gene expression | | ✓ | | | | | | | | | | | | | | | | | | |
| there is an additive effect of genes that contributes to the phenotype | | ✓ | | | | | | | | | | | | | | | | | | |
| there are distinct differences between the various forms of a characteristic | ✓ | | | | | | | | | | | | | | | | | | | |
| 5(b)(i) | <i>ref. to spread of results about the <u>mean</u> ;</i> | | | 1 | | | | | | | | | | | | | | | | |

PUBLISHED

| Question | Answer | Marks |
|-----------|---|----------|
| 5(b)(ii) | <p>$t = 4.255$;;;</p> <p>give 2 marks: if answer is 4.25 or 4.26 if answer is more than 4 significant figures e.g. 4.255439871 if answer is incorrectly rounded to 4 significant figures e.g. 4.256</p> <p>if answer incorrect then max 2 for working numerator = 4.2 denominator = 0.986972</p> <p>ecf - if no working mark given then allow one mark for 12.02 as the answer</p> | 3 |
| 5(b)(iii) | <p>1 there is a higher (mean) concentration of serum 25-OHD in summer ; ora</p> <p>any two from:</p> <p>2 value of $t / 4.255 > \text{critical value} / 3.773$;</p> <p>3 there is a <u>significant difference</u> between the two means ;</p> <p>4 any <u>difference</u> is not due to chance / <u>difference</u> due to chance less than 0.0001% ;</p> <p>ecf from incorrect answer to 5bii</p> | 3 |
| 5(b)(iv) | <p>genetic AND environmental OR an example of a genetic cause AND an example of an environmental cause ;</p> | 1 |

PUBLISHED

| Question | Answer | Marks |
|----------|---|-------|
| 6(a)(i) | redox ; | 1 |
| 6(a)(ii) | blue to colourless ; | 1 |
| 6(b)(i) | <p>any two from:</p> <p>1 volume / mass / concentration, of yeast suspension ;</p> <p>2 volume / mass / concentration, of glucose (solution) ;</p> <p>3 volume / concentration, of DCPIP ;</p> <p>4 AVP ; e.g. time when DCPIP is added / pH</p> | 2 |
| 6(b)(ii) | <p>any three from:</p> <p>1 the less time taken (for DCPIP) to change colour the higher the rate of respiration ; ora</p> <p><i>rate increases up to 40 °C</i></p> <p>2 due to increase in, kinetic energy / KE ;</p> <p>3 due to more enzyme-substrate complexes formed or due to more (successful / effective) collisions between enzymes and substrates or more enzyme catalysed reactions ;</p> <p><i>rate decreases after 40 °C</i></p> <p>4 due to denaturation of (named respiration) enzyme ;</p> <p>5 further detail ; e.g. active site shape change / optimum temperature 40 °C</p> | 3 |

PUBLISHED

| Question | Answer | Marks |
|----------|---|----------|
| 7(a) | 1 calculate R_f value(s) ; 2 $(R_f =) \frac{\text{distance moved by pigment (from baseline)}}{\text{distance moved by solvent (from baseline)}}$; 3 compare with, known / standard / table, values ; | 3 |
| 7(b) | any three from: 1 absorb light wavelengths not absorbed by, reaction centre / primary pigment / chlorophyll a ; A harvest 2 so extend the range of wavelengths absorbed ; 3 pass energy to, reaction centre / primary pigment / chlorophyll a ; 4 <i>ref. to accessory pigments</i> ; | 3 |

PUBLISHED

| Question | Answer | Marks |
|----------|---|----------|
| 7(c) | <p><i>any seven from:</i></p> <ol style="list-style-type: none"> 1 carbon dioxide, reacts / combines, with, ribulose biphosphate / RuBP ; 2 (catalysed by) rubisco ; 3 <i>ref. to</i> carbon (dioxide) fixation ; 4 unstable 6C compound ; 5 forms 2 (molecules of) glycerate 3-phosphate / GP ; 6 glycerate 3-phosphate / GP, reduced to, triose phosphate / TP ; 7 by reduced NADP and ATP ; 8 triose phosphate / TP, used to regenerate RuBP ; 9 glycerate 3-phosphate / GP, forms amino acids ; 10 (some) TP forms, (named) hexoses / sucrose / maltose / starch / cellulose / glycerol / lipids / amino acids ; 11 <i>ref. to</i> Calvin cycle ; | 7 |

| Question | Answer | Marks | | | | | | | | | | | | | | | | | | | | | | |
|---------------|---|---------------|-----------------|---|----------|---|----------|---|----------|---|----------|---|----------|---|----------|---|----------|---|----------|---|----------|----|----------|----------|
| 8(a)(i) | X – Schwann (cell) ; Ignore myelin sheath (as not a cell) Y – cell body ; A cytoplasm | 2 | | | | | | | | | | | | | | | | | | | | | | |
| 8(a)(ii) | intermediate neurone ; A relay neurone / sensory neurone | 1 | | | | | | | | | | | | | | | | | | | | | | |
| 8(b) | <table border="1" data-bbox="338 416 999 1137"> <thead> <tr> <th data-bbox="338 416 658 481">correct order</th> <th data-bbox="658 416 999 481">letter of stage</th> </tr> </thead> <tbody> <tr><td data-bbox="338 481 658 547">1</td><td data-bbox="658 481 999 547">C</td></tr> <tr><td data-bbox="338 547 658 612">2</td><td data-bbox="658 547 999 612">F</td></tr> <tr><td data-bbox="338 612 658 678">3</td><td data-bbox="658 612 999 678">A</td></tr> <tr><td data-bbox="338 678 658 743">4</td><td data-bbox="658 678 999 743">E</td></tr> <tr><td data-bbox="338 743 658 809">5</td><td data-bbox="658 743 999 809">J</td></tr> <tr><td data-bbox="338 809 658 874">6</td><td data-bbox="658 809 999 874">I</td></tr> <tr><td data-bbox="338 874 658 940">7</td><td data-bbox="658 874 999 940">G</td></tr> <tr><td data-bbox="338 940 658 1005">8</td><td data-bbox="658 940 999 1005">B</td></tr> <tr><td data-bbox="338 1005 658 1070">9</td><td data-bbox="658 1005 999 1070">H</td></tr> <tr><td data-bbox="338 1070 658 1137">10</td><td data-bbox="658 1070 999 1137">D</td></tr> </tbody> </table> <p data-bbox="338 1174 685 1240"> C F A E all above J ; C F A E in correct order ; </p> <p data-bbox="338 1276 685 1342"> I G B H between J and D ; I G B H in correct order ; </p> | correct order | letter of stage | 1 | C | 2 | F | 3 | A | 4 | E | 5 | J | 6 | I | 7 | G | 8 | B | 9 | H | 10 | D | 4 |
| correct order | letter of stage | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | C | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | F | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | A | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | E | | | | | | | | | | | | | | | | | | | | | | | |
| 5 | J | | | | | | | | | | | | | | | | | | | | | | | |
| 6 | I | | | | | | | | | | | | | | | | | | | | | | | |
| 7 | G | | | | | | | | | | | | | | | | | | | | | | | |
| 8 | B | | | | | | | | | | | | | | | | | | | | | | | |
| 9 | H | | | | | | | | | | | | | | | | | | | | | | | |
| 10 | D | | | | | | | | | | | | | | | | | | | | | | | |

PUBLISHED

| Question | Answer | Marks |
|----------|--|----------|
| 8(c) | <p><i>any four from:</i></p> <p><i>allow 'no' for 'less' or 'fewer'</i></p> <p>1 less / fewer, Ca²⁺ enter (pre)synaptic knob ;</p> <p>2 less / fewer, vesicles, move to / fuse with, presynaptic membrane ;</p> <p>3 less, ACh released / exocytosis of ACh ;</p> <p>4 less binding of ACh to receptors (on sarcolemma) ;</p> <p>5 fewer, Na⁺ channels open / Na⁺ enter (muscle fibre) ;</p> <p>6 less depolarisation of sarcolemma / threshold potential not reached / fewer action potentials generated ; Ignore postsynaptic membrane</p> <p>7 less Ca²⁺ released from SR / less binding of Ca²⁺ to troponin / fewer sites exposed / fewer cross bridges ;</p> | 4 |

| Question | Answer | Marks |
|----------|---|----------|
| 9(a) | <p><i>any three from:</i></p> <p>1 loss of habitat / example ;</p> <p>2 hunted / poaching / increased predation ;</p> <p>3 climate change / example ;</p> <p>4 competition for, food / resources / example ;</p> <p>5 new disease ;</p> <p>6 illegal pet / fur, trade ;</p> | 3 |

PUBLISHED

| Question | Answer | Marks | | | | | | | | | | | | | | |
|----------|--|----------|-----------------------|------|---|------|---------|------|-----|------|-----|------|-----------|------|-----|----------|
| 9(b) | <p>1 large / steep, increase from 1980 to 1990 ;</p> <p>2 plateau / remains constant or slight changes / fluctuates ;</p> <p>3 data quote (two numbers and two years) ;</p> <table border="1" data-bbox="338 419 880 876"> <thead> <tr> <th>year</th> <th>number of lemurs born</th> </tr> </thead> <tbody> <tr> <td>1970</td> <td>5</td> </tr> <tr> <td>1980</td> <td>32 / 33</td> </tr> <tr> <td>1990</td> <td>175</td> </tr> <tr> <td>2000</td> <td>175</td> </tr> <tr> <td>2010</td> <td>184 / 185</td> </tr> <tr> <td>2020</td> <td>170</td> </tr> </tbody> </table> | year | number of lemurs born | 1970 | 5 | 1980 | 32 / 33 | 1990 | 175 | 2000 | 175 | 2010 | 184 / 185 | 2020 | 170 | 3 |
| year | number of lemurs born | | | | | | | | | | | | | | | |
| 1970 | 5 | | | | | | | | | | | | | | | |
| 1980 | 32 / 33 | | | | | | | | | | | | | | | |
| 1990 | 175 | | | | | | | | | | | | | | | |
| 2000 | 175 | | | | | | | | | | | | | | | |
| 2010 | 184 / 185 | | | | | | | | | | | | | | | |
| 2020 | 170 | | | | | | | | | | | | | | | |
| 9(c)(i) | <p><i>any three from:</i></p> <p>1 stress (in captivity) ;</p> <p>2 reproductive cycle disrupted ;</p> <p>3 may reject mate / refuse to breed / do not have correct (courtship) behaviour ;</p> <p>4 lack of suitable mates ;</p> <p>5 enclosure too small / not natural environment ;</p> <p>6 expensive ;</p> <p>7 AVP ; e.g. inbreeding</p> | 3 | | | | | | | | | | | | | | |

PUBLISHED

| Question | Answer | Marks |
|----------|---|-------|
| 9(c)(ii) | increase / maintain, genetic diversity / heterozygosity / hybrid vigour / gene pool OR reduce, inbreeding depression / homozygosity ; | 1 |

| Question | Answer | Marks |
|----------|---|-------|
| 10(a) | <p>any four from:</p> <ol style="list-style-type: none"> 1 changes in factor / stimulus, detected by receptor ; 2 <i>ref. to</i> CNS / brain / coordinator ; 3 impulses / (named) hormone, sent to, (named) effector / muscle / gland ; 4 (named) effector / muscle / gland, carries out response ; 5 factor returns to, set point / norm ; 6 negative feedback ; 7 AVP ; e.g. cell signalling | 4 |

PUBLISHED

| Question | Answer | Marks |
|----------|---|----------|
| 10(b) | <p><i>any three from:</i> <i>cell signalling carries on</i></p> <p>1 / 2 two details ;; e.g. glucagon binds to receptors / adenylyl cyclase stimulated / G protein activated / cAMP formed / protein kinase A activated / enzyme cascade</p> <p>3 no / less, (functioning) glycogen phosphorylase (produced) OR non-functioning glycogen phosphorylase (produced) OR no / less, glycogen phosphorylase activated ;</p> <p>4 change in, tertiary structure / active site ;</p> <p>5 (so) less / no, glycogen converted to glucose / glycogenolysis ;</p> | 3 |
| 10(c) | <p><i>any three from:</i></p> <p>1 no / less, (functioning) glycogen synthase (produced) or non-functioning glycogen synthase (produced) or no / less, glycogen synthase activated ;</p> <p>2 high / increase in, blood glucose <u>concentration</u> (following this meal) ;</p> <p>3 (so) glucose (excreted) in urine ;</p> <p>4 more lipid synthesis ;</p> <p>5 inhibits release of glucagon ;</p> <p>6 AVP ; e.g. affects blood water potential / dehydration / thirst / tiredness / coma / affects blood pressure</p> | 3 |